Table 1 Characteristics of the study population. Patients were dichotomized according to the FMD

Age (years)

Mean (SD)

64 (11)

63 (10)

64 (12)

0.6

Sex

0.059

 Female

n (%)

20 (28%)

6 (18%)

14 (38%)

 Male

n (%)

51 (72%)

28 (82%)

23 (62%)

ASA

0.9

 1

n (%)

1 (1.4%)

0 (0%)

1 (2.7%)

 2

n (%)

54 (76%)

27 (79%)

27 (73%)

 3

n (%)

16 (23%)

7 (21%)

9 (24%)

BMI (kg/m²)

Mean (SD)

25.7 (4.1)

26.9 (3.8)

24.6 (4.1)

0.016

Smoking

n (%)

30 (42%)

16 (47%)

14 (38%)

0.4

Charlson Comorbidity index

Median (IQR)

2.00 (1.00)

2.00 (1.00)

2.00 (1.00)

0.2

SORT score

Median (IQR)

1.48 (1.69)

1.48 (1.69)

1.48 (1.69)

> 0.9

rCRI ≥ 2

n (%)

39 (55%)

20 (59%)

19 (51%)

0.5

Hypertension

n (%)

33 (46%)

18 (53%)

15 (41%)

0.3

Coronary heart disease

n (%)

7 (9.9%)

3 (8.8%)

4 (11%)

> 0.9

Dyslipidemia

n (%)

9 (13%)

3 (8.8%)

6 (16%)

0.5

ACE inihibtor intake

n (%)

12 (17%)

4 (12%)

8 (22%)

0.3

AT1 antagonist intake

n (%)

10 (14%)

8 (24%)

2 (5.4%)

0.041

Statine intake

n (%)

12 (17%)

8 (24%)

4 (11%)

0.2

Surgery duration (min)

Mean (SD)

301 (104)

320 (98)

284 (106)

0.14

Surgery type

0.11

 Non-Oesophagectomy

n (%)

32 (45%)

12 (35%)

20 (54%)

 Oesophagectomy

n (%)

39 (55%)

22 (65%)

17 (46%)

DAH30

Median (IQR)

14 (6)

14 (4)

15 (8)

0.8

CCI

Median (IQR)

21 (36)

26 (38)

21 (30)

0.4

Clavien-Dindo score

0.3

 0

n (%)

20 (28%)

10 (29%)

10 (27%)

 I

n (%)

11 (15%)

4 (12%)

7 (19%)

 II

n (%)

21 (30%)

8 (24%)

13 (35%)

 IIIa

n (%)

6 (8.5%)

3 (8.8%)

3 (8.1%)

 IIIb

n (%)

8 (11%)

7 (21%)

1 (2.7%)

 IVa

n (%)

3 (4.2%)

1 (2.9%)

2 (5.4%)

 IVb

n (%)

2 (2.8%)

1 (2.9%)

1 (2.7%)

 V

n (%)

0 (0%)

0 (0%)

0 (0%)

Complications

0.12

 Major (CD ≥ IIIa)

n (%)

19 (27%)

12 (35%)

7 (19%)

 Minor (CD < IIIa)

n (%)

52 (73%)

22 (65%)

30 (81%)

FMD (%)

Median (IQR)

10 (8)

7 (4)

15 (11)

< 0.001